 |
Click HERE for details on the Oligo Fund
Search Term: Oligodendroglioma High Grade
Search results are returned below separately for clinical trials, frequently asked questions, pages on this site, and news articles - scroll down to see them all!
Trials and Noteworthy Treatments
|
|
|
|
|
|
Previous 25 Treatment Next 25
|
|
Location |
|
Last Updated |
|
|
|
Details |
|
Phase I Trial of Aflibercept (VEGF Trap)with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Gliomas |
|
New York, NY
Pittsburgh, PA
Houston, TX
San Antonio, TX
Madison, WI |
|
10/27/2008 |
|
|
|
|
|
Details |
|
BIBW 2992 with or without daily temozolomide in the treatment of
patients with recurrent malignant glioma
|
|
Charlottesville, VA |
|
10/20/2008 |
|
|
|
Details |
|
Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma |
|
Charlottesville, VA |
|
09/30/2008 |
|
|
|
|
|
Details |
|
Gliogene: An International Brain Tumor Study |
|
Houston, TX |
|
07/24/2008 |
|
|
|
Details |
|
Phase I/II Trial of Irinotecan plus Lenalidomide in Adult Patients with Recurrent Glioblastoma Multiforme |
|
Houston, TX |
|
05/28/2008 |
|
|
|
|
|
Details |
|
Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients with Malignant Glioma |
|
Houston, TX |
|
05/28/2008 |
|
|
|
Details |
|
Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults with Recurrent Glioblastoma Multiforme
|
|
Houston, TX |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma
|
|
Houston, TX |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Los Angeles, CA
Boston, MA
Durham, NC
New York, NY
Houston, TX |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma |
|
Houston, TX |
|
04/15/2008 |
|
|
|
Details |
|
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients |
|
Los Angeles, CA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Phase I Study of Glioma-Associated Antigen (GAA) Peptide-Pulsed Dendritic Cell Vaccination in Malignant Glioma Patients |
|
Los Angeles, CA |
|
03/02/2008 |
|
|
|
Details |
|
Phase I Study of Immunization With Autologous Tumor Lysate-Pulsed Dendritic Cells in Patients With Malignant Gliomas (Vaccine Therapy in Treating Patients With Malignant Glioma) |
|
Los Angeles, CA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Phase I/II Study of GP96 Heat Shock Protein-Peptide Complex Vaccine in Patients With Recurrent or Progressive High-Grade Glioma |
|
San Francisco, CA |
|
03/02/2008 |
|
|
|
Details |
|
Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System |
|
Los Angeles, CA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
A phase I/II Evaluation of Vaccination with Type-1 Dendritic Cells Pulsed With Multiple Peptides In the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas |
|
Pittsburgh, PA |
|
03/02/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Kingston, Ontario, CANADA
Edmonton, Alberta, CANADA
Moncton, New Brunswick, CANADA
Ottawa, Ontario, CANADA
Toronto, Ontario, CANADA
Winnipeg, Manitoba, CANADA
Phoenix, AZ
La Jolla, CA
Palo Alto, CA
Sacramento, CA
Aurora, CO
Englewood, CO
Jacksonville, FL
Orlando, FL
Chicago, IL
Evanston, IL
Boston, MA
Detroit, MI
Winston-Salem, NC
Edison, NJ
Buffalo, NY
Columbus, OH
Columbus, OH
Portland, OR
Memphis, TN
Nashville, TN
Seattle, WA
Madison, WI |
|
03/01/2008 |
|
|
|
|
|
Details |
|
Phase II Study Of 7 Days On/7 Days Off Temozolomide In Patients With High-Grade Glioma |
|
San Francisco, CA |
|
01/17/2008 |
|
|
|
Details |
|
NABTC 04-03: A Phase I Study of Vorinostat (Suberolyanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas |
|
San Francisco, CA |
|
10/03/2007 |
|
|
|
|
|
Details |
|
NABTC 04-02: Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
|
|
Los Angeles, CA
Boston, MA
Durham, NC
New York, NY
Pittsburgh, PA
Houston, TX
San Antonio, TX
Madison, WI |
|
10/03/2007 |
|
|
|
Details |
|
A Phase 1/11 Study of Topotecan by Intracerebral Clysis for the Treatment of Recurrent Primary Malignant Brain Tumors |
|
NEW YORK CITY, NY |
|
08/20/2007 |
|
|
|
|
|
Details |
|
A Phase I Study of Imatinib Mesylate (Gleevec) in Combination With Temozolomide (Temodar) in Patients With Malignant Glioma |
|
Durham, NC |
|
08/20/2007 |
|
|
|
Details |
|
A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas |
|
Chicago, IL |
|
08/20/2007 |
|
|
|
|
|
Details |
|
Determination of the In-Tumor-Concentration of Imatinib Mesylate (Gleevec) in Malignant Glioma After Oral Administration |
|
Baltimore, MD |
|
08/20/2007 |
|
|
|
Details |
|
A Phase II Trial With Bevacizumab (Avastin) and Irinotecan (CPT-11) for Patients With Primary Brain Tumors and Progression After Standard Therapy |
|
Copenhagen, Denmark |
|
08/18/2007 |
|
|
|
|
|
News Stories
Frequently Asked Questions
|
|
